<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2022-5064</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-5064</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Количественная оценка исходной концентрации кальций-фосфатных бионов как скринингового маркера минерального гомеостаза крови у пациентов с сердечно-сосудистыми заболеваниями и у пациентов с хронической болезнью почек</article-title><trans-title-group xml:lang="en"><trans-title>Quantification of the initial levels of calciprotein particles as a screening marker of mineral homeostasis in patients with cardiovascular disease and in patients with chronic kidney disease</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1518-3888</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шишкова</surname><given-names>Д. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Shishkova</surname><given-names>D. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дарья Кирилловна Шишкова — кандидат биологических наук, научный сотрудник лаборатории молекулярной, трансляционной и цифровой медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">shishkovadk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4146-3373</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Матвеева</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Matveeva</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вера Геннадьевна Матвеева — кандидат медицинских наук, старший научный сотрудник лаборатории клеточных технологий отдела экспериментальной медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">matveeva_vg@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6652-5745</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>В. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>V. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виктория Евгеньевна Маркова — младший научный сотрудник лаборатории молекулярной, трансляционной и цифровой медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">markve97@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6620-5960</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хрячкова</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Khryachkova</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Николаевна Хрячкова — кандидат биологических наук, младший научный сотрудник лаборатории геномной медицины отдела экспериментальной медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">oksana_hryachkova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6911-6568</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Индукаева</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Indukaeva</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Владимировна Индукаева — кандидат медицинских наук, старший научный сотрудник лаборатории эпидемиологии сердечно-сосудистых заболеваний отдела оптимизации медицинской помощи при сердечно-сосудистых заболеваниях.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">indelen@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9734-8462</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шабаев</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Shabaev</surname><given-names>А. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Амин Рашитович Шабаев — младший научный сотрудник лаборатории клеточных технологий отдела экспериментальной медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">neirohirurgi@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2366-6545</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фролов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Frolov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Алексей Витальевич Фролов — кандидат медицинских наук, младший научный сотрудник лаборатории рентгенэндоваскулярной и реконструктивной хирургии сердца и сосудов отдела хирургии сердца и сосудов.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">kjerne@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8679-4857</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутихин</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutikhin</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Антон Геннадьевич Кутихин — кандидат медицинских наук, заведующий лабораторией молекулярной, трансляционной и цифровой медицины.</p><p>Кемерово</p></bio><bio xml:lang="en"><p>Kemerovo</p></bio><email xlink:type="simple">antonkutikhin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт комплексных проблем сердечнососудистых заболеваний</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute for Complex Issues of Cardiovascular Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>04</day><month>01</month><year>2023</year></pub-date><volume>27</volume><issue>12</issue><fpage>5064</fpage><lpage>5064</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шишкова Д.К., Матвеева В.Г., Маркова В.Е., Хрячкова О.Н., Индукаева Е.В., Шабаев А.Р., Фролов А.В., Кутихин А.Г., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Шишкова Д.К., Матвеева В.Г., Маркова В.Е., Хрячкова О.Н., Индукаева Е.В., Шабаев А.Р., Фролов А.В., Кутихин А.Г.</copyright-holder><copyright-holder xml:lang="en">Shishkova D.K., Matveeva V.G., Markova V.E., Khryachkova O.N., Indukaeva E.V., Shabaev А.R., Frolov A.V., Kutikhin A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/5064">https://russjcardiol.elpub.ru/jour/article/view/5064</self-uri><abstract><sec><title>Цель</title><p>Цель. Оценить исходную концентрацию кальций-фосфатных бионов (КФБ), являющихся скевенджерами избыточного кальция и фосфора, в крови у пациентов с сердечно-сосудистыми заболеваниями и у пациентов с хронической болезнью почек в сравнении с условно здоровыми донорами крови.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование было включено 308 субъектов: 1) 88 участников эпидемиологического исследования PURE, не имеющих гемодинамически значимого каротидного атеросклероза и симптоматического коронарного атеросклероза; 2) 88 пациентов с цереброваскулярной болезнью (ЦВБ), потребовавшей каротидной эндартерэктомии; 3) 88 пациентов с ишемической болезнью сердца (ИБС), потребовавшей чрескожного коронарного вмешательства или коронарного шунтирования; 4) 63 пациента с хронической болезнью почек 5 стадии (ХБП5). У пациентов в сыворотке определяли базовые биохимические показатели минерального гомеостаза (уровень общего и ионизированного кальция, фосфора, общего белка, альбумина и фетуина-А) и исходную концентрацию КФБ в сыворотке крови при помощи флюоресцентно меченного бисфосфоната OsteoSense 680EX методом проточной цитометрии.</p></sec><sec><title>Результаты</title><p>Результаты. В сравнении со всеми остальными категориями пациентов условно здоровые доноры крови характеризовались наибольшей концентрацией КФБ в сыворотке (249 КФБ/мкл), что свидетельствует о сохранной способности крови к компенсации нарушений минерального гомеостаза путем агрегации избыточного кальция и фосфора с кислыми белками. Сниженная исходная концентрация КФБ у пациентов с ЦВБ (170 КФБ/мкл), ИБС (139 КФБ/мкл) и ХБП5 (193-203 КФБ/мкл) указывала на нарушение способности агрегировать избыточный кальций и фосфор, что также было отражено повышенным уровнем ионизированного кальция в крови.</p></sec><sec><title>Заключение</title><p>Заключение. Пациенты с ЦВБ, ИБС и ХБП5 характеризуются сниженной исходной концентрацией КФБ в крови в сравнении с условно здоровыми донорами, что в сочетании с повышенным уровнем ионизированного кальция и сниженным уровнем альбумина позволяет предположить истощение кальций-связывающей способности сыворотки у пациентов с сердечно-сосудистыми и почечными заболеваниями.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To evaluate the initial concentration of calciprotein particles (CPPs), which are scavengers of excessive calcium and phosphate, in patients with cardiovascular disease and in patients with chronic kidney disease as compared with the healthy volunteers.</p></sec><sec><title>Material and methods</title><p>Material and methods. The study included 308 individuals as follows: 1) 88 participants of the PURE study without hemodynamically relevant carotid athero scle rosis and symptomatic coronary atherosclerosis; 2) 88 patients with cere brovascular disease (CVD) who required carotid endarterectomy; 3) 88 pa tients with coronary artery disease (CAD) who required percutaneous coronary intervention or coronary artery bypass graft surgery; 4) 63 patients with stage 5 chronic kidney disease (CKD). We measured following mineral homeostasis parameters: total and ionized calcium, phosphate, total protein, albumin, and fetuin-A. Then, we determined a baseline serum CPP concentration by flow cytometry using a fluorescent-labeled bisphosphonate OsteoSense 680EX. Results. In comparison with other patients, healthy volunteers had the highest serum CPP concentration (249 CPPs/µL), indicating the retained ability to compensate mineral homeostasis disturbances by aggregation of excessive calcium and pho sphate with acidic proteins (mineral chaperones). Reduced serum CPP concentration in patients with CVD (170 CPPs/µL), CAD (139 CPPs/µL), and stage 5 CKD (193-203 CPPs/µL) showed impaired aggregation of excessive serum calcium and phosphate, which was also reflected by an increased level of blood ionized calcium.</p></sec><sec><title>Conclusion</title><p>Conclusion. Patients with CVD, CAD, and stage 5 CKD have lower serum CPP concentration than healthy individuals. In combination with elevated ionized calcium and reduced albumin, this suggests the depletion of calcium binding buffers in the serum of patients with cardiovascular and renal diseases.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>сердечно-сосудистые заболевания</kwd><kwd>минеральный гомеостаз</kwd><kwd>кальций</kwd><kwd>фосфор</kwd><kwd>кальций-фосфатные бионы</kwd><kwd>проточная цитометрия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiovascular diseases</kwd><kwd>mineral homeostasis</kwd><kwd>calcium</kwd><kwd>phosphate</kwd><kwd>cal ciprotein particles</kwd><kwd>flow cytometry</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kobylecki CJ, Nordestgaard BG, Afzal S. Plasma Ionized Calcium and Risk of Cardiovascular Disease: 106 774 Individuals from the Copenhagen General Population Study. Clin Chem. 2021;67(1):265-75. doi:10.1093/clinchem/hvaa245.</mixed-citation><mixed-citation xml:lang="en">Kobylecki CJ, Nordestgaard BG, Afzal S. Plasma Ionized Calcium and Risk of Cardiovascular Disease: 106 774 Individuals from the Copenhagen General Population Study. Clin Chem. 2021;67(1):265-75. doi:10.1093/clinchem/hvaa245.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ginsberg C, Houben AJHM, Malhotra R, et al. Serum Phosphate and Microvascular Function in a Population-Based Cohort. Clin J Am Soc Nephrol. 2019;14(11):1626-33. doi:10.2215/CJN.02610319.</mixed-citation><mixed-citation xml:lang="en">Ginsberg C, Houben AJHM, Malhotra R, et al. Serum Phosphate and Microvascular Function in a Population-Based Cohort. Clin J Am Soc Nephrol. 2019;14(11):1626-33. doi:10.2215/CJN.02610319.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Campos-Obando N, Lahousse L, Brusselle G, et al. Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men. Eur J Epidemiol. 2018;33(9):85971. doi:10.1007/s10654-018-0407-7.</mixed-citation><mixed-citation xml:lang="en">Campos-Obando N, Lahousse L, Brusselle G, et al. Serum phosphate levels are related to all-cause, cardiovascular and COPD mortality in men. Eur J Epidemiol. 2018;33(9):85971. doi:10.1007/s10654-018-0407-7.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Back M, Aranyi T, Cancela ML, et al. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Front Cardiovasc Med. 2019;5:196. doi:10.3389/fcvm.2018.00196.</mixed-citation><mixed-citation xml:lang="en">Back M, Aranyi T, Cancela ML, et al. Endogenous Calcification Inhibitors in the Prevention of Vascular Calcification: A Consensus Statement From the COST Action EuroSoftCalcNet. Front Cardiovasc Med. 2019;5:196. doi:10.3389/fcvm.2018.00196.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Uedono H, Mori K, Ochi A, et al. Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells. Sci Rep. 2021;11(1):7486. doi:10.1038/s41598-021-86881-0.</mixed-citation><mixed-citation xml:lang="en">Uedono H, Mori K, Ochi A, et al. Effects of fetuin-A-containing calciprotein particles on posttranslational modifications of fetuin-A in HepG2 cells. Sci Rep. 2021;11(1):7486. doi:10.1038/s41598-021-86881-0.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Xie WM, Ran LS, Jiang J, et al. Association between fetuin-A and prognosis of CAD: A systematic review and meta-analysis. Eur J Clin Invest. 2019;49(5):e13091. doi:10.1111/eci.13091.</mixed-citation><mixed-citation xml:lang="en">Xie WM, Ran LS, Jiang J, et al. Association between fetuin-A and prognosis of CAD: A systematic review and meta-analysis. Eur J Clin Invest. 2019;49(5):e13091. doi:10.1111/eci.13091.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shishkova DK, Velikanova EA, Bogdanov LA, et al. Calciprotein Particles Link Disturbed Mineral Homeostasis with Cardiovascular Disease by Causing Endothelial Dysfunction and Vascular Inflammation. Int J Mol Sci. 2021;22(22):12458. doi:10.3390/ijms222212458.</mixed-citation><mixed-citation xml:lang="en">Shishkova DK, Velikanova EA, Bogdanov LA, et al. Calciprotein Particles Link Disturbed Mineral Homeostasis with Cardiovascular Disease by Causing Endothelial Dysfunction and Vascular Inflammation. Int J Mol Sci. 2021;22(22):12458. doi:10.3390/ijms222212458.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Shishkova D, Markova V, Sinitsky M, et al. Calciprotein Particles Cause Endo thelial Dysfunction under Flow. Int J Mol Sci. 2020;21(22):8802. doi:10.3390/ijms21228802.</mixed-citation><mixed-citation xml:lang="en">Shishkova D, Markova V, Sinitsky M, et al. Calciprotein Particles Cause Endo thelial Dysfunction under Flow. Int J Mol Sci. 2020;21(22):8802. doi:10.3390/ijms21228802.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Smith ER, Hewitson TD, Cai MMX, et al. A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci Rep. 2017;7(1):5686. doi:10.1038/s41598-017-05474-y.</mixed-citation><mixed-citation xml:lang="en">Smith ER, Hewitson TD, Cai MMX, et al. A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci Rep. 2017;7(1):5686. doi:10.1038/s41598-017-05474-y.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ruderman I, Smith ER, Toussaint ND, et al. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secon dary hyperparathyroidism. BMC Nephrol. 2018;19(1):113. doi:10.1186/s12882-018-0910-9.</mixed-citation><mixed-citation xml:lang="en">Ruderman I, Smith ER, Toussaint ND, et al. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secon dary hyperparathyroidism. BMC Nephrol. 2018;19(1):113. doi:10.1186/s12882-018-0910-9.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bressendorff I, Hansen D, Pasch A, et al. The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial. Nephrol Dial Transplant. 2021;36(4):713-21. doi:10.1093/ndt/gfz234.</mixed-citation><mixed-citation xml:lang="en">Bressendorff I, Hansen D, Pasch A, et al. The effect of increasing dialysate magnesium on calciprotein particles, inflammation and bone markers: post hoc analysis from a randomized controlled clinical trial. Nephrol Dial Transplant. 2021;36(4):713-21. doi:10.1093/ndt/gfz234.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Кутихин А. Г., Шишкова Д. К., Хрячкова О. Н. и др. Законо мерности формирования кальций-фосфатных бионов у пациентов с каротидным и коронарным атеросклерозом. Российский кардиологический журнал. 2020;25(12):3881. doi:10.15829/1560-4071-2020-3881.</mixed-citation><mixed-citation xml:lang="en">Kutihin AG, Shishkova DK, Hryachkova ON, et al. Formation of calcium phosphate bions in patients with carotid and coronary atherosclerosis. Russian Journal of Cardiology. 2020;25(12):3881. (In Russ.) doi:10.15829/1560-4071-2020-3881.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bojic M, Koller L, Cejka D, et al. Propensity for Calcification in Serum Associates With 2-Year Cardiovascular Mortality in Ischemic Heart Failure With Reduced Ejection Frac tion. Front Med (Lausanne). 2021;8:672348. doi:10.3389/fmed.2021.672348.</mixed-citation><mixed-citation xml:lang="en">Bojic M, Koller L, Cejka D, et al. Propensity for Calcification in Serum Associates With 2-Year Cardiovascular Mortality in Ischemic Heart Failure With Reduced Ejection Frac tion. Front Med (Lausanne). 2021;8:672348. doi:10.3389/fmed.2021.672348.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bundy JD, Cai X, Scialla JJ, et al. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2019;73(6):806-14. doi:10.1053/j.ajkd.2019.01.024.</mixed-citation><mixed-citation xml:lang="en">Bundy JD, Cai X, Scialla JJ, et al. Serum Calcification Propensity and Coronary Artery Calcification Among Patients With CKD: The CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2019;73(6):806-14. doi:10.1053/j.ajkd.2019.01.024.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27-39. doi:10.1161/CIRCULATIONAHA.114.013876.</mixed-citation><mixed-citation xml:lang="en">Moe SM, Chertow GM, Parfrey PS, et al. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27-39. doi:10.1161/CIRCULATIONAHA.114.013876.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
